Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
BOSTON--(BUSINESS WIRE)--
Akili, Inc. (Nasdaq: AKLI), a leading digital medicine company, today announced that management will present at a fireside chat and participate in a panel discussion on prescription digital therapeutics at the virtual LifeSci Partners HealthTech Symposium on Tuesday, September 20, 2022.
Details are as follows:
Format: Presentation and Fireside Chat
Time:9:30 a.m. ET
Format: Panel Discussion
Topic: Prescription Digital Therapeutics
Time:11:30 a.m. ET
Live and archived webcasts of the fireside chat and panel discussion will be available on the Investors section of Akili’s website at www.akiliinteractive.com.
About Akili
Akili is pioneering the development of cognitive treatments through game-changing technologies. Our approach of leveraging technologies designed to directly target the brain establishes a new category of medicine – medicine that is validated through clinical trials like a drug or medical device but experienced like entertainment. Akili’s platform is powered by proprietary therapeutic engines designed to target cognitive impairment at its source in the brain, informed by decades of research and validated through rigorous clinical programs. Driven by Akili’s belief that effective medicine can also be fun and engaging, Akili’s products are delivered through captivating action video game experiences. For more information, please visit www.akiliinteractive.com.